 |
||
|
||
 |
 |
|
Ascenta Therapeutics
Novel small molecules for the treatment of cancer.
USVP Contact:
Jon Root
print version
Bayhill Therapeutics
Biopharmaceutical company developing therapies for the treatment of autoimmune diseases, including multiple sclerosis and Type I diabetes, based on technologies that originated in Prof. Lawrence Steiman, M.D.'s laboratory at Stanford.
USVP Contact:
Phil Young and Jon Root
print version
Calithera Biosciences
A pioneer in activation therapeutics, the company is developing novel small molecule cancer drugs that activate caspases, the enzymes that control programmed cell death.
USVP Contact:
Larry Lasky and Jon Root
print version
Cleave
Developing small molecule therapeutics for cancer
USVP Contact:
Larry Lasky and Jon Root
print version
Genta (GETA)
Develops biopharmaceuticals for anti-viral and anti-cancer treatments.
USVP Contact:
Bill Bowes
print version
Glycomed
Glycomed (acquired by Ligand) develops pharmaceuticals based on complex carbohydrate bioactivity.
USVP Contact:
Bill Bowes
print version
Ilypsa
Ilypsa (acquired by Amgen) is a therapeutics platform spinout of Symx that develops novel polymer-based, orally bioavailable therapies to treat renal failure and metabolic disorders.
USVP Contact:
Jon Root
print version
Intellikine
A leader in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway for treatment of cancer, inflammation, and autoimmune diseases.
USVP Contact:
Larry Lasky and Jon Root
print version
OncoMed Pharmaceuticals
Developing innovative pharmaceuticals for solid tumors, based on the recent identification of cancer stem cells.
USVP Contact:
Jon Root
print version
Proteolix
Proteolix (acquired by Onyx > Pharmaceuticals) is a biopharmaceutical company committed to the discovery, clinical development and marketing of drugs that inhibit the proteasome-mediated protein degradation pathway in cells for the treatment of cancer.
USVP Contact:
Jon Root
print version
Vical (VICL)
Researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases.
USVP Contact:
Phil Young
print version
Xoma (XOMA)
Develops biopharmaceuticals that target cancer, immunological disorders and infectious diseases. Its product, RAPTIVA, is the first FDA-approved biologic therapy designed to provide continuous control of chronic moderate-to-severe plaque psoriasis.